A Novel CD133- and EpCAM-Targeted Liposome With Redox-Responsive Properties Capable of Synergistically Eliminating Liver Cancer Stem Cells

Journal article

Cancer stem-like cells (CSCs) identified by self-renewal ability and tumor-initiating potential are responsible for tumor recurrence and metastasis in many cancers. Conventional chemotherapy fails to eradicate CSCs that hold a state of dormancy and possess multi-drug resistance. Spurred by the progress of nanotechnology for drug delivery and biomedical applications, nanomedicine has been increasingly developed to tackle stemness-associated chemotherapeutic resistance for cancer therapy. This review focuses on advances in nanomedicine-mediated therapeutic strategies to overcome chemoresistance by specifically targeting CSCs, the combination of chemotherapeutics with chemopotentiators, and programmable controlled drug release. Perspectives from materials and formulations at the nano-scales are specifically surveyed. Future opportunities and challenges are also discussed

Authors: Wang, Z; Sun, M; Li, W; Fan, L; Zhou, Y

• Publication status: Published
• Peer review status: Peer reviewed
• Publisher: Frontiers Media
• Journal: Frontiers in Chemistry
• Volume: 8
• Pages: 649-649
• Publication date: 2020-08-11
• DOI: 10.3389/fchem.2020.00649
• EISSN: 2296-2646
• ISSN: 2296-2646
• Language: English
• Keywords: Stem cell; Doxorubicin; Cancer; Cancer stem cell; Cell biology; Epithelial cell adhesion molecule; Biotechnology; Hepatocellular carcinoma; Drug delivery; Glutathione; Cancer research; Cancer cell; Chemotherapy; Cell; Biochemistry; Biology; Chemistry; Liposome; Endocytosis; Liver cancer; In vivo; Nanocarriers